A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis
A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis
复制标题
DOI：
10.1016/j.jcf.2020.04.012
复制
发表时间：
2020-05-01
影响因子：
5.2
通讯作者：
Carr, Siobhan B.
中科院分区：
文献类型：
--
作者：
Cosgriff, Rebecca;Ahern, Susannah;Carr, Siobhan B.
关于新型冠状病毒SARS-CoV-2对囊性纤维化（CF）患者的临床影响，缺乏相关信息。我们的目的是在囊性纤维化患者中检测SARS-CoV-2感染。研究方法：使用标准化模板报告每个参与国家提交给其国家CF注册中心的匿名数据，然后进行整理和总结。结果：8个国家报告了40例病例。在40例病例中，31例（78%）在就诊时有SARS-CoV-2症状，24例（60%）有发热。70%已痊愈，30%在报告时仍未消退，未报告死亡病例。结论：该早期报告显示，在该异质性CF队列中，SARS-CoV-2恢复良好。该病的病程似乎与一般人群没有区别，但目前的数字太小，无法得出确切的结论，CF患者应继续严格遵循公共卫生建议，以保护自己免受感染。(C)2020年，任作家。由Elsevier B. V.代表欧洲囊性纤维化协会出版。
Information is lacking on the clinical impact of the novel coronavirus, SARS-CoV-2, on people with cystic fibrosis (CF). Our aim was to characterise SARS-CoV-2 infection in people with cystic fibrosis. Methods: Anonymised data submitted by each participating country to their National CF Registry was reported using a standardised template, then collated and summarised. Results: 40 cases have been reported across 8 countries. Of the 40 cases, 31 (78%) were symptomatic for SARS-CoV-2 at presentation, with 24 (60%) having a fever. 70% have recovered, 30% remain unresolved at time of reporting, and no deaths have been submitted. Conclusions: This early report shows good recovery from SARS-CoV-2 in this heterogeneous CF cohort. The disease course does not seem to differ from the general population, but the current numbers are too small to draw firm conclusions and people with CF should continue to strictly follow public health advice to protect themselves from infection. (C) 2020 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.